共 50 条
Comparison of Four Botulinum Neurotoxin Type A Preparations in the Treatment of Hyperdynamic Forehead Lines in Men: A Pilot Study
被引:1
|作者:
de Morais, Orlando Oliveira
[1
]
Reis-Filho, Eugenio Matos
[2
]
Pereira, LarissaVilela
[3
]
Gomes, Ciro Martins
Alves, Gilvan
[3
]
机构:
[1] Univ Brasilia, Univ Hosp Brasilia, Dept Dermatol, BR-70910900 Brasilia, DF, Brazil
[2] Hosp Reg Asa Norte, Brasilia, DF, Brazil
[3] Aepit Clin Dermatol, Brasilia, DF, Brazil
关键词:
TOXIN TYPE-A;
DOUBLE-BLIND;
BOTOX;
D O I:
暂无
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background: Botulinum neurotoxin type A (BTXA) offers a minimally invasive approach for the treatment of facial rhytides and has been well accepted by male patients. However, few comparative studies about the efficacy of the different BTXA preparations in this emerging group of patients are available. Objective: To access the efficacy of four BTXA preparations in the treatment of hyperdynamic forehead lines in men. Methods: Twelve male patients with a mean age of 30.5 +/- 5.26 years, with moderate or severe hyperdynamic forehead lines on a facial wrinkle scale (FWS), were involved in the study. Using an intra-individual controlled study design, either 17 mouse units (m.U) of Botox, Prosigne, and Xeomin or 51 Speywood units (s.U) of Dysport were applied to each side of a patient's forehead. Subjects with absent or mild forehead lines were considered responders. Study evaluations were performed monthly up to day 150. Results: All patients responded in a side-to-side evaluation and no asymmetries or differences in the degree of reduction of hyperdynamic forehead lines were noted at day 30 and day 60 (P=0.340). Analysis of all combined forehead sides treated with a given BTXA did not show statistically significant differences in terms of maintenance of improvement between different BTXA preparations at day 150 (P=0.528). Conclusion: The data obtained in this study revealed a similar effectiveness of the BTXA preparations evaluated in the treatment of hyperdynamic forehead lines in men, when considering a dose-ratio of 1 m.U of Botox, Xeomin or Prosigne to 3 s.U of Dysport.
引用
收藏
页码:216 / 219
页数:4
相关论文